Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer
-
Published:2024-11
Issue:
Volume:86
Page:101113
-
ISSN:2590-0412
-
Container-title:Respiratory Medicine and Research
-
language:en
-
Short-container-title:Respiratory Medicine and Research
Author:
Moro-Sibilot DenisORCID,
Falchero Lionel,
Ardin Camille,
Zouak Ayoube,
Molinier Olivier,
Romand Philippe,
Leleu Olivier,
Amrane Karim,
Berndt Célia,
Langlais Alexandra,
Morin Franck,
Westeel Virginie
Funder
AstraZeneca
AstraZeneca SAS